Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 28.75 USD -2.97% Market Closed
Market Cap: 4.1B USD
Have any thoughts about
Denali Therapeutics Inc?
Write Note

Denali Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Denali Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Denali Therapeutics Inc
NASDAQ:DNLI
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%

Denali Therapeutics Inc
Revenue Breakdown

Breakdown by Geography
Denali Therapeutics Inc

Not Available

Breakdown by Segments
Denali Therapeutics Inc

Total Revenue: 330.5m USD
100%
Atv:abeta Program License: 288.9m USD
87.4%
Cns Program License: 25m USD
7.6%
Ptv:pgrn Collaboration Agreement: 10m USD
3%
Option Research Services: 1.6m USD
0.5%
Show More
Show Less

See Also

What is Denali Therapeutics Inc's Revenue?
Revenue
0 USD

Based on the financial report for Sep 30, 2024, Denali Therapeutics Inc's Revenue amounts to 0 USD.

Back to Top